Abstract
Introduction: Patients with locally advanced rectal cancer (LARC) are undergoing neoadjuvant chemoradiotherapy (NCRT) prior to surgery. Although in some patients the NCRT is known to prevent local recurrence, it is also accompanied by side effects. Accordingly, there is an unmet need to identify predictive markers allowing to identify non-responders to avoid its adverse effects. We monitored circulating tumor DNA (ctDNA) as a potential liquid biopsy-based biomarker. We have investigated ctDNA changes plasma during the early days of NCRT and its relationship to the overall therapy outcome.
Methods and Patients: The studied cohort included 36 LARC patients (stage II or III) undergoing NCRT with subsequent surgical treatment. We have detected somatic mutations in tissue biopsies taken during endoscopic examination prior to the therapy. CtDNA was extracted from patient plasma samples prior to therapy and at the end of the first week. In order to optimize the analytical costs of liquid-biopsy testing, we have utilized a two-level approach in which first a low-cost detection method of denaturing capillary electrophoresis was used followed by examination of initially negative samples by a high-sensitivity BEAMING assay. The ctDNA was related to clinical parameters including tumor regression grade (TRG) and TNM tumor staging.
Results: We have detected a somatic mutation in 33 out of 36 patients (91.7%). Seven patients (7/33, 21.2%) had ctDNA present prior to therapy. The ctDNA positivity before treatment reduced post-operative disease-free survival and overall survival by an average of 1.47 and 1.41 years, respectively (p = 0.015, and p = 0.010). In all patients, ctDNA was strongly reduced or completely eliminated from plasma by the end of the first week of NCRT, with no correlation to any of the parameters analyzed.
Conclusions: The baseline ctDNA presence represented a statistically significant negative prognostic biomarker for the overall patient survival. As ctDNA was reduced indiscriminately from circulation of all patients, dynamics during the first week of NCRT is not suited for predicting the outcome of LARC. However, the general effect of rapid ctDNA disappearance apparently occurring during the initial days of NCRT is noteworthy and should further be studied.
Introduction
Current treatment of rectal cancer is based on a multimodal approach involving surgery, radiation, and systemic therapies (1). The actual therapeutic decision process is based on a precise disease staging with early tumors being preferentially considered for direct surgical treatment. Patients with locally advanced rectal cancer (LARC), that is, stages II and III, should undergo radiation in combination with systemic chemotherapy prior to surgery. This neoadjuvant chemoradiotherapy (NCRT) typically includes 5-fluoropyrimidine administered within either a “long regimen” involving a total dosage 50.4 Gy (45 Gy split into 25 fractions received within 5 weeks and initial boost 5.4 Gy) or a “short regimen” of 25 Gy in five fractions during the first week. Although records show that NCRT in general does not improve the overall survival (OS), it reduces the local recurrence of RC to under 10% of all cases (2). Patients showing appropriate response to NCRT have a significantly better prognosis in the long-term perspective (3, 4).
The clinical and laboratory evaluation following NCRT includes endoscopic examination, MRI, and histopathology (5). The objective response to NCRT may include (i) a complete elimination of the tumor, (ii) partial regression of the tumor size, (iii) elimination or reduction of the number of tumor-positive lymph nodes in the mesorectum, or (iv) any combination thereof. Although a complete clinical response is found in 15–30% of all cases and partial response is reached in 20–5% of all patients, half of the tumors will remain principally unaffected following NCRT (3, 4). At the same time, however, it is known that NCRT induces a variety of adverse side effects, most importantly development of fibrosis due to the post-radiative pelvic damage leading to impairment of the anal sphincter, leading to incontinence and erectile dysfunction. It is also associated with post-operative complications and worsening of post-operative functional results (6, 7). In order to avoid and/or minimize the adverse effects of NCRT, it is highly desirable to modify or even eliminate preoperative NCRT in potential non-responders.
Identification of patients non-responding to NCRT has recently become a focus of sustained clinical research. A wide spectrum of approaches has been investigated including application of various predictive markers. The traditional clinical parameters such as tumor size and distance from anal margin (evaluated by endoscopy and MRI) were complemented by laboratory biomarkers comprising, for example, hemoglobin, carcinoembryonic antigen (CEA) serum levels, or tumor-infiltrating lymphocytes (8). Furthermore, use of a contrast MRI with diffusion-weighted imaging (DWI), which accounts for perfusion and cellular density and thus reflects tumor biology, has also been utilized. However, to this point, study results have been generally contradictory (9–15).
More recently, a role of molecular genetic markers of NCRT response prediction was investigated. Among others, variants of the KRAS gene (MIM# 190070), which is mutated in 30–60% sporadic colorectal cancer (CRC), are the most frequently studied genetic “biomarkers” (16). Activating pathogenic variants (henceforward termed in legacy nomenclature “mutations”) in KRAS are associated with poor response to biological therapy as monitored by monoclonal anti-epidermal growth factor receptor (anti-EGFR) antibodies (17). Several studies have assessed KRAS as a predictive marker for the therapeutic effect of NCRT, indicating better response of the wild type over its mutated alleles (18, 19). This concept, however, has not been confirmed by others (20, 21). In addition, because mutations in the TP53 gene (MIM# 191170) have also been frequently observed in CRC, it was suggested that it could serve as a potential predictor of resistance to NCRT. Several groups implied that TP53 gene wild-type constitution and a lower expression of the p53 protein product are both associated with proper therapeutic response (22–24). Nonetheless, these studies have not been universally accepted, and further studies are needed (25, 26).
Detection of DNA circulating in the blood of patients [cell-free DNA (cfDNA)] has recently gained considerable interest as a potentially new class of molecular markers in the area of cancer diagnostics and management (27). CfDNA consists of short DNA fragments released from decomposing tumor cells mainly through necrotic and apoptotic processes as well as active endosomal release. Its levels are significantly elevated in organisms undergoing cellular decomposition induced by immune response such as owing to infection or inflammation as well as cancer. The typical levels of cfDNA range approximately from 10 to 100 ng/ml of plasma (~3,000–30,000 DNA copies/ml) in healthy individuals up to mg/ml levels in cancer patients (28). The part originating from cancerous cells is referred to as a circulating tumor DNA (ctDNA). CtDNA, which represents only a very small fraction of the overall cfDNA, typically contains somatic mutations, which are only present in tumor and not in the “healthy” cells, hence, presents an alternative source for predictive cancer-specific mutation detection. This fact has been intensely investigated giving rise to a whole new area of ctDNA “liquid biopsy-based” diagnostic strategies. Aside from being used as an alternative source of material for tumor diagnostics, the relative changes in ctDNA levels are known to correlate with the overall tumor burden in a given patient, thus indirectly reflecting the overall size and number of cancerous lesions present in the body (29). Therefore, ctDNA evaluation has a great potential as a marker for monitoring the disease and course of the treatment (30). It has long been recognized that in a positive response to chemotherapy, the ctDNA is reduced or eliminated completely from the peripheral circulation (31–33).
According to recent reports, the natural kinetics of cfDNA levels in blood is a bimodal process in which initially high levels are rapidly decreasing within minutes as the cfDNA fragments are being distributed across highly vascularized organs/tissues and in other biological fluids followed by a period of slower elimination processes (34). The elimination process is through DNA degradation by ribonucleases present in the blood with a typical half-life of 1.5–3 h. The equilibrium between release and elimination supports the use of cfDNA as a marker of concurrent processes taking place in the body. It is universally accepted that tumors responding to radiotherapy exhibit cell damage leading to necrosis by which DNA is rapidly released into the bloodstream. Hence, upon administration of the radiotherapy, ctDNA levels should rise momentarily before being removed from the circulation by natural homeostatic processes.
In this study, we investigated tumor-derived DNA in plasma (ctDNA) in a pilot cohort of patients with LARC undergoing NCRT. The aim of the present work was to observe changes in ctDNA levels in rectal cancer patients during the initial days of the NCRT treatment and to correlate these to the overall clinical outcome of RC therapy.
Patients and Methods
Patient Cohort and Neoadjuvant Chemoradiotherapy Therapy
Our prospective study included 36 patients with LARC who had been recruited between 2013 and 2017. The group included 27 men and 9 women with an average age of 64.1 years, capable of undergoing repeated blood sampling during therapy. Patient characteristics are listed in Table 1. The study protocol was approved by the ethics committee of Motol University Hospital, and patients confirmed their study participation by signing an informed consent form. Upon initial recommendation of the committee, only patients with good performance status and compliance were included in the study.
Table 1
| TNM staging I | TNM staging II | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patient | Gender | Age | Stage | T | N | M | T | N | M | L | TRG | Mutation | Baseline ctDNA |
| 1 | M | 68 | 2 | 3 | 0 | 0 | 3 | 0 | 0 | 3 | 2 | TP53 | 0 |
| 2 | M | 63 | 2 | 3 | 0 | 0 | 0 | 0 | 0 | 1 | 4 | KRAS | 0 |
| 3 | M | 73 | 3 | 3 | 1 | 0 | 3 | 2a | 0 | 2 | 2 | KRAS+APC | 0 |
| 4 | M | 74 | 2 | 3 | 0 | 0 | 3 | 2a | 0 | 2 | 1 | KRAS | 0 |
| 5 | F | 73 | 3 | 3 | 1 | 0 | 2 | 0 | 0 | 2 | 2 | PIK3CA | 0 |
| 6 | M | 64 | 3 | 4 | 1 | 0 | 3 | 1c | 0 | 3 | 1 | APC | 0 |
| 7 | M | 62 | 3 | 3 | 1 | 0 | 3 | 2b | 0 | 3 | 2 | TP53+APC | 0 |
| 8 | F | 36 | 3 | 3 | 1 | 0 | 2 | 0 | 0 | 2 | 2 | APC | 0 |
| 9 | F | 61 | 3 | 3 | 1 | 0 | 0 | 0 | 0 | 2 | 4 | TP53 | 0 |
| 10 | M | 70 | 3 | 3 | 1 | 0 | 2 | 0 | 0 | 2 | 2 | KRAS+PIK3CA | 0 |
| 11 | M | 64 | 2 | 3 | 0 | 0 | 2 | 0 | 0 | 2 | 3 | 0 | 0 |
| 12 | M | 79 | 2 | 3 | 0 | 0 | 3 | 1a | 0 | 2 | 2 | TP53 | 0 |
| 13 | F | 59 | 2 | 3 | 0 | 0 | 3 | 0 | 0 | 2 | 1 | KRAS+TP53 | 0 |
| 14 | M | 61 | 3 | 3 | 1 | 0 | 3 | 2a | 0 | 2 | 1 | KRAS+TP53 | x |
| 15 | M | 62 | 2 | 3 | 0 | 0 | 3 | 0 | 0 | 3 | 2 | TP53/PIK3CA | 0 |
| 16 | M | 53 | 3 | 3 | 1 | 0 | 3 | 1a | 0 | 2 | 2 | APC | 0 |
| 17 | M | 79 | 2 | 3 | 0 | 0 | 2 | 0 | 0 | 1 | 2 | KRAS | 0 |
| 18 | M | 64 | 2 | 3 | 1 | 0 | 3 | 1a | 0 | 2 | 2 | TP53 | 0 |
| 19 | M | 72 | 3 | 2 | 1 | 0 | 2 | 2b | 0 | 3 | 2 | BRAF/TP53 | 0 |
| 20 | F | 30 | 3 | 1 | 1 | 0 | 1 | 1b | 0 | 2 | 1 | KRAS/TP53 | x |
| 21 | F | 64 | 3 | 2 | 1 | 0 | 1 | 0 | 0 | 2 | 2 | KRAS/APC | 0 |
| 22 | M | 60 | 3 | 3 | 1 | 0 | 3 | 0 | 0 | 2 | 2 | 0 | 0 |
| 23 | F | 74 | 3 | 3 | 1 | 0 | 3 | 2b | 0 | 2 | 1 | KRAS | 0 |
| 24 | M | 63 | 3 | 3 | 1 | 0 | 1 | 0 | 0 | 2 | 2 | TP53 | 0 |
| 25 | M | 74 | 3 | 3 | 1 | 0 | 1 | 0 | 0 | 1 | 2 | KRAS | x |
| 26 | F | 66 | 2 | 4 | 0 | 0 | 2 | 0 | 0 | 3 | 1 | KRAS | x |
| 27 | M | 52 | 3 | 3 | 1 | 0 | 2 | 0 | 0 | 2 | 1 | KRAS/APC | x |
| 28 | M | 64 | 2 | 3 | 0 | 0 | 2 | 1c | 0 | 2 | 3 | KRAS | x |
| 29 | M | 83 | 3 | 3 | 1 | 0 | 3 | 2a | 0 | 1 | 2 | KRAS | x |
| 30 | M | 74 | 3 | 3 | 2 | 0 | 3 | 0 | 0 | 2 | 1 | KRAS | 0 |
| 31 | M | 62 | 3 | 3 | 2 | 0 | 3 | 2 | 0 | 2 | 1 | TP53 | 0 |
| 32 | F | 63 | 3 | 3 | 1 | 0 | 0 | 0 | 0 | 3 | 4 | APC | 0 |
| 33 | M | 58 | 3 | 3 | 1 | 0 | 2 | 0 | 0 | 3 | 2 | KRAS | 0 |
| 34 | M | 58 | 3 | 3 | 0 | 0 | 3 | 0 | 0 | 3 | 2 | KRAS | 0 |
| 35 | M | 63 | 3 | 3 | 1 | 0 | 2 | 1 | 0 | 1 | 1 | KRAS | 0 |
| 36 | M | 62 | 3 | 3 | 1 | 0 | 3 | 0 | 0 | 3 | 2 | 0 | 0 |
Patient characteristics.
ctDNA, circulating tumor DNA; Stage, clinical stage of the disease; TNM staging I, before treatment; TNM staging II, after surgery according to histopathology report; L, tumor location (1, upper rectum; 2, middle rectum; 3, lower rectum); TRG, tumor regression grade according to Dworak (0, no response; 1, minimal response; 2, moderate response; 3, near complete response; 4, complete response).
Initial endoscopic biopsy was performed, and the tumor was histologically verified. Staging of the disease was determined based on the CT and MRI (Table 1), and the respective treatment was protocol based on these examinations. Tumor tissues (typically a total of three samples acquired by biopsy forceps) collected during the initial endoscopy prior to oncological treatment were immediately post-operatively frozen at −30°C and sent to the collaborating laboratory for genetic testing. Subsequently, tumor tissues were examined for the presence of the most common mutations previously observed in CRC (comprising KRAS /MIM# 190070/, TP53 /MIM# 191170/, APC /MIM# 611731/, PIK3CA /MIM# 171834/, BRAF /MIM# 164757/, and CTNNB1 /MIM# 166806/). Plasma was obtained by centrifugation from blood samples taken prior to and during NCRT.
All patients underwent NCRT consisting of 50.4 Gy of radiation and concomitant administration of Xeloda™ (capecitabine) at a dose of 825 mg/m2. Irradiation was carried out by 25 fractions with initial boost of 5.4 Gy. At the end of the first week of NCRT, another blood sample was taken for ctDNA examination. A control MRI of the pelvis was performed 6 weeks after termination of NCRT. At 8–10 weeks after the end of NCRT, all patients with LARC underwent surgery. Biopsy samples were evaluated in detail by an expert histopathologist using standard TNM staging. In addition, the “Dworak histopathological tumor regression grade” (TRG) was also determined. Patients were followed up for at least 3 years after surgery. Standard tumor marker examination, colonoscopy, and computed tomography (CT) imaging were performed at regular intervals.
Tissue and Circulating Tumor DNA Mutation Testing
DNA extraction from tumor tissue bioptates and plasma was performed using standard spin-column procedures. A GenElute™ Mammalian Genomic DNA Miniprep Kit (Sigma Aldrich, St. Louis, Missouri, USA) was used for extraction from the tissue samples. Extraction of ctDNA from blood plasma samples was performed using NucleoSpin Plasma XS kit (Macherey-Nagel, Düren, Germany), the volume of plasma processed was 600 μl, yielding typically between 5 and 50 ng of cfDNA per sample determined by Qubit 2.0 Fluorometer (Life Technologies, Camarillo, CA).
Similarly to works of others (31–33), the mutation analysis of tissue samples was focused on a panel of selected oncogenes, with the highest proportion of somatic mutations in rectal cancer according to the international “COSMIC database” (https://cancer.sanger.ac.uk/cosmic). This panel included the hotspots in KRAS, BRAF, PIK3CA, and CTNNB1, as well as selected areas of tumor suppressor genes APC (mutation cluster region) and TP53 (exons 5–8). Mutation analyses were performed using the denaturing capillary electrophoresis (DCE) method using the previously described experimental parameters (35–38). Somatic mutations detected in the tissue samples were subsequently examined in samples of cfDNA obtained from plasma. Genetic testing was conducted using two separate methods as discussed further. A subgroup of ctDNA samples assigned as negative by DCE method (39) was subsequently retested using a high-resolution “BEAMING assay” (40) directed at the detection of KRAS-specific ctDNA and provided by an external contracted laboratory (Department of Pathology, Jessenius Medical Faculty of Comenius University in Martin, Slovakia). The details of the multilevel ctDNA testing approach are illustrated in Figure 1 and further detailed in the Discussion section.
Figure 1
Statistical Methods
All statistical analyses were performed using R language for statistical computing and graphics (41). Associations between survival period and other predictors such as the presence of ctDNA prior and during NCRT were analyzed using the Cox proportional hazard model and t-tests and plotted using boxplots and Kaplan–Meier curves, respectively. Outputs with p-values below 0.05 were assumed to be statistically significant.
Results
The objective response to NCRT is included in patient characteristics listed in Table 1. The best response characterized by Dworak TRG score of 3 or 4 was observed in five patients (5/36, 13.9%), whereas 11 patients (11/36, 30.5%) showed none or very limited tumor regression (TRG score 0 or 1). Both results were in a range of typically observed response frequencies as described by others (3, 4). When evaluating the effect of NCRT on the disease stage, some patients exhibited a shift toward the lower TNM (such as that illustrated in Figures 2, 3) mainly owing to the reduction of tumor mass and nodal status.
Figure 2
Figure 3
As the tumor tissue biopsies were evaluated prior to therapy, somatic mutations were detected in samples from 33 out of 36 patients (91.7%) using the six-gene panel. As expected, the mutation testing has revealed the presence of combinations of multiple mutations, mainly with concurrent presence of KRAS or TP53 with another mutation type (shown in Table 1). There was no relation between the presence of a specific mutation (or a mutation combination) in the tumor tissue and the ultimate outcome of NCRT evaluated by either TRG or TNM staging.
With the combination of the low-resolution and high-resolution methods, ctDNA was detected in plasma samples of seven patients prior to NCRT (7/33, 21.2%), and it showed a prognostic role. Whereas, the overall probability of a 3-year survival in all patients was 86.7%, the value was 91.2% in ctDNA-negative subgroup and 71.4% in ctDNA-positive subgroup. Hence, as shown using boxplots in Figure 4, comparing both groups of patients with positive and negative ctDNA and not considering the time-event dimension and proved by t-tests, the ctDNA-positive status prior to NCRT was significantly associated with an shorter disease-free survival (DFS) and a shorter OS by an average of 1.47 and 1.41 years, respectively [t(DFS)= 2.95, df(DFS)= 9.88, p(DFS)= 0.015 (approx.), and t(OS)= 3.15, df(OS)= 10.31, p(OS)= 0.010 (approx.)]. The effect is further documented within, assuming the time-event associations by Kaplan–Meier analysis for DFS and OS (Figure 5).
Figure 4
Figure 5
The early dynamics of ctDNA revealed an interesting phenomenon as shown in Figure 6. Surprisingly, during the first week of NCRT, ctDNA has been indiscriminately eliminated or significantly reduced from circulation in all patients. Accordingly, there was no association between the change in ctDNA levels (before and during NCRT) and TRG or TNM staging.
Figure 6
Discussion
In this pilot study, we aimed to provide additional evidence of the effect of NCRT in LARC using various predictive biomarkers. There were several reports in the literature investigating the association between the presence of cfDNA as well as ctDNA and the prediction of an NCRT therapeutic response in rectal tumors. Zitt et al. evaluated cfDNA levels in LARC before and after NCRT and following surgical interventions (42). Studied cases were divided into NCRT non-responders and responders. The median level of pretreatment cfDNA was 4.2 ng/ml, after termination of CRT 1 ng/ml, and after surgery 4.1 ng/ml. The authors found that pretreatment levels of cfDNA of non-responders and responders do not significantly differ. At the end of treatment, cfDNA levels were higher in the non-responder cohort. In almost all patients, cfDNA levels substantially decreased toward the end of the NCRT regimen. However, the major limitation of this study is the overall small number of analyzed cases (n = 26).
In 2011, Agostini et al. published a set of 67 cases with LARC (43). These clinical investigators measured cfDNA levels before, during, and after NCRT. They determined the total cfDNA concentration and the proportion of long and short DNA fragments, thus establishing a “DNA integrity index.” Like Zitt et al., also, these authors did not observe a significant correlation between the pretreatment cfDNA levels and the response to NCRT. However, they provided evidence that NCRT responders had a significantly lower DNA integrity index than non-responders following NCRT.
Sun et al. have verified that cfDNA levels in CRC patients are significantly higher than in healthy subjects (44). Furthermore, they determined the plasma concentration of two DNA fragments (100 and 400 bp) before and after NCRT, and they found that the 400-bp fragment concentration was significantly lower in the responder group after termination of NCRT, thus demonstrating a higher level of fragmentation.
Carpinetti et al. performed whole-genome sequencing of tumor DNA and thus determined specific DNA fragments for each of four patients (19). The authors searched for ctDNA fragments in patients' plasma and demonstrated that in patients with good treatment response, ctDNA levels decreased during NCRT. When ctDNA increased again, it was associated with cancer progression and preceded the rise of CEA and the manifestation of recurrence detected by various imaging approaches. However, this study suffers from a rather small number of analyzed cases. Similarly, Li et al. detected ctDNA levels before and during NCRT. In this study, the prediction of treatment response based on ctDNA positivity before NCRT was 70% (45). On the contrary, Yang et al., in a larger group of patients, did not confirm the association between the pretreatment level of ctDNA and the response to NCRT in patients with RC (46).
In our study, we have hypothesized that early changes in plasma ctDNA reflect the immediate effect of NCRT and thus will be of utility in predicting its therapeutic efficiency. Hence, we expected that upon evaluation of ctDNA plasma dynamics, we will be able to differentiate NCRT non-responders, sparing them from adverse effects of continued/aggressive cancer treatment schemes. Accordingly, we have determined the ctDNA levels prior to NCRT and immediately at the end of the first week of NCRT. In addition, we aimed to find potential correlations with mutations in a panel of six commonly examined genes.
A large variation in baseline ctDNA positivity is apparent from previous reports ranging from 15 to 77% in various groups of LARC patients (47). In order to reduce high cost associated with liquid biopsy testing to enable for future cost-effective routine diagnostic approach, we have in this work employed a “cascade” approach (Figure 1). In this regard, we have always started evaluation with a relatively very simple and fast singleplex PCR method that required only a relatively small amount of samples (600 μl of plasma). This “Level 1” method, the DCE, was capable of revealing a ctDNA presence at >1% of minor allele fraction (MAF) (39, 47) in just 2 h. In case of a negative result, we performed in “Level 2” a high-resolution BEAMING assay. BEAMING (which stands for beads, emulsion, amplification, and magnetics) utilizes a digital droplet PCR resulting in amplified product of individual ctDNA fragments being bound to individual magnetic beads and subsequently detected by flow cytometry. The approach, which is performed using a dedicated instrumentation, exhibits sensitivities down to 0.01% (MAF) on residual amounts of archived ctDNA that were left after DCE Level 1 testing. In this study, only patients exhibiting tumors with KRAS mutation could be subjected to Level 2 testing, owing to the specificity of the BEAMING technology. Level 1 (DCE) testing revealed ctDNA positivity in five patients (5/30, 16.7%), and Level 2 (BEAMING) revealed ctDNA positivity in two more patients (2/4, 50%). The overall yield from this multilevel testing approach was 23.3% (7/30), mainly due to the limitation of BEAMING testing directed at KRAS ctDNA mutations only. Indeed, other high-sensitivity alternative techniques would improve this; nonetheless, the obtained frequency is comparable with previously observed results for stages II and III in rectal cancer (29).
Contrary to our expectations, we have not observed any predictive correlation between the baseline ctDNA levels and the actual outcome of NCRT in terms of TRG or TNM staging. Yet when the prognostic effect was evaluated, patients showing baseline ctDNA positivity have exhibited a shorter progression-free survival and OS (Figure 6). This is in agreement with previous work by Tie et al., who have reported ctDNA as a negative prognostic factor for the overall patient survival (48). For most ctDNA-positive patients, imaging has, indeed, subsequently revealed a presence of previously unrecognized micrometastatic sites. The ctDNA positivity should therefore be considered to guide therapy-related decisions following surgical treatment as similarly applied in breast (49) or colorectal cancer (50, 51).
Intriguingly, in all patients, we have observed a strong reduction or complete elimination of ctDNA at the end of the first NCRT week. Counterintuitively, ctDNA levels were reduced regardless of the eventual clinical outcome. Apparently, this unequivocal rapid ctDNA clearance following the therapy dose suggests presence of a more general phenomenon not related to the actual patient characteristics or specific tumor biology. The ctDNA removal from plasma is primarily a result of enzymatic digestion (34, 52). It has been reported recently that some DNA exonucleases active in DNA repair are released as a result of radiation damage (53). It can only be speculated that such a radiation-induced activity of exonucleases could result in a temporal effect of ctDNA clearance following the administration of NCRT. In order to elucidate the aforementioned phenomena, ctDNA monitoring should be performed at even shorter time intervals. Although most papers describing the use of ctDNA in palliative chemotherapy (54, 55) and, more recently, immunotherapy (56) apply monitoring with initial sampling at day 7 or later, it may well be necessary to perform examination at even shorter intervals of days or hours from the therapy start, respectively. Recently, a similar approach directed at the evaluation of ctDNA in urine has recently been recently applied for monitoring of daily dynamics of tumor response to targeted anticancer therapy in non-small-cell lung cancer (NSCLC) (57). When performed during the initial phase of the NCRT, possibly within hours from receiving the first radiation fraction together with chemotherapy and continuing for the next several days, such approach could substantiate ctDNA dynamics underlying eventual transient changes in tumor morphology and its damage, including subsequent ctDNA uptake resulting from the administered multimodal therapy. Thus, understanding of the detailed timing of ctDNA release and clearance may be essential for the long-awaited applicability of the ctDNA-based therapy outcome prediction for NCRT treatment of LARC patients (58) and beyond.
Conclusions
In the present work, we have demonstrated the utility of monitoring of early changes in ctDNA levels in patients with LARC undergoing NCRT prior to surgical treatment. By applying a multilevel ctDNA detection approach, we were able to monitor ctDNA dynamics in seven patients receiving NCRT. We have evaluated the previously reported preoperative presence of ctDNA as a negative prognostic factor, which may be useful in direction of patients for adjuvant therapy following surgery.
We have observed a clear reduction of ctDNA levels in all patients during the initial week of NCRT, but without any direct association to the objective clinical response evaluated by TRG or TNM. As a consequence, we could not predict the response to preoperative NCRT in LARC on the basis of the ctDNA levels. Although such observations might exclude the use of early ctDNA changes as a predictive biomarker of NCRT outcome, our findings may open new research avenues on the mechanisms of ctDNA release and clearance upon cellular damage due to the combined effects of chemoradiation.
Statements
Data availability statement
The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation, to any qualified researcher.
Ethics statement
The studies involving human participants were reviewed and approved by ethics committee Motol University Hospital. The patients/participants provided their written informed consent to participate in this study. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.
Author contributions
FP: designed study, organized and followed up the patient cohort, collected samples, and prepared and drafted manuscript. MMi: designed study, and prepared and drafted manuscript. TH and BB: processed and analyzed samples. MMa: prepared a revised manuscript. LS: performed a statistical analysis. LB: managed molecular testing of patients and revised manuscript. JH: designed study and overseeing clinical part of project. All authors contributed to the article and approved the submitted version.
Funding
This work was supported by the Czech Ministry of Health Grant No. AZV 15-27939A.
Acknowledgments
The authors would like to thank Prof. Lukas Plank at the Department of Pathology, Jessenius Medical Faculty of Comenius University and University Hospital, in Martin, Slovakia, along with Sysmex Slovakia, for processing selected ctDNA samples using the BEAMING technology. The authors wish to thank Renata Ptackova at Genomac Research Institute for her valuable comments.
Conflict of interest
MMi and BB are employed by Elphogene. MMi has an ownership stake in Elphogen. LB has stock ownership in Genomac Research Institute, a private research organization. LB and TH are employed by Genomac Research Institute. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
- CEA
carcinoembryonic antigen
- cfDNA
cell-free DNA
- CRC
colorectal cancer
- CT
computed tomography
- ctDNA
circulating tumor DNA
- DCE
denaturing capillary electrophoresis
- DWI
diffusion-weighted imaging
- LARC
locally advanced rectal cancer
- MRI
magnetic resonance imaging
- NCRT
neoadjuvant chemoradiotherapy
- RC
rectal cancer
- TNM staging
TNM Classification of Malignant Tumors
- TRG
Dworak histopathological tumor regression grade.
Abbreviations
References
1.
Glynne-JonesRWyrwiczLTiretEBrownGRödelCCervantesAet al. Rectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. (2017) 28(Suppl. 4):iv22–40. 10.1093/annonc/mdx224
2.
PahlmanLBoheMCedermarkBDahlbergMLindmarkGSjodahlRet al. The Swedish rectal cancer registry. Br J Surg. (2007) 94:1285–92. 10.1002/bjs.5679
3.
FokasELierschTFietkauRHohenbergerWBeissbarthTHessCet al. Tumor regression grading after preoperative chemoradiotherapy for locally advanced rectal carcinoma revisited: updated results of the CAO/ARO/AIO-94 trial. J Clin Oncol. (2014) 32:1554–62. 10.1200/JCO.2013.54.3769
4.
SongCChungJ-HKangS-BKimD-WOhH-KLeeHSet al. Impact of tumor regression grade as a major prognostic factor in locally advanced rectal cancer after neoadjuvant chemoradiotherapy: a proposal for a modified staging system. Cancers. (2018) 10:319. 10.3390/cancers10090319
5.
DworakOKeilholzLHoffmannA. Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorectal Dis. (1997) 12:19–23. 10.1007/s003840050072
6.
ContinPKuluYBrucknerTSturmMWelschTMüller-StichBPet al. Comparative analysis of late functional outcome following preoperative radiation therapy or chemoradiotherapy and surgery or surgery alone in rectal cancer. Int J Colorect Dis. (2014) 29:165–75. 10.1007/s00384-013-1780-z
7.
BirgissonHPahlmanLGunnarssonUGlimeliusB. Adverse effects of preoperative radiation therapy for rectal cancer: long-term follow-up of the Swedish rectal cancer trial. J Clin Oncol. (2005) 23:8697–705. 10.1200/JCO.2005.02.9017
8.
DaydeDTanakaIJainRTaiMCTaguchiA. Predictive and prognostic molecular biomarkers for response to neoadjuvant chemoradiation in rectal cancer. Int J Mol Sci. (2017) 18:573. 10.3390/ijms18030573
9.
VaupelPThewsOHoeckelM. Treatment resistance of solid tumors: role of hypoxia and anemia. Med Oncol. (2001) 18:243–59. 10.1385/MO:18:4:243
10.
DeVriesAFKremserCHeinPAGriebelJKrezcyAOfnerDet al. Tumor microcirculation and diffusion predict therapy outcome for primary rectal carcinoma. Int J Radiat Oncol Biol Phys. (2003) 56:958–65. 10.1016/S0360-3016(03)00208-6
11.
DevriesAFGriebelJKremserCJudmaierWGneitingTKreczyAet al. Tumor microcirculation evaluated by dynamic magnetic resonance imaging predicts therapy outcome for primary rectal carcinoma. Cancer Res. (2001) 61:2513–6. 10.1016/s0360-3016(02)03106-1
12.
KremserCTriebTRudischAJudmaierWde VriesA. Dynamic T(1) mapping predicts outcome of chemoradiation therapy in primary rectal carcinoma: sequence implementation and data analysis. J Magn Reson Imaging. (2007) 26:662–71. 10.1002/jmri.21034
13.
LambrechtMVandecaveyeVDe KeyzerFRoelsSPenninckxFVan CutsemEet al. Value of diffusion-weighted magnetic resonance imaging for prediction and early assessment of response to neoadjuvant radiochemotherapy in rectal cancer: preliminary results. Int J Radiat Oncol Biol Phys. (2012) 82:863–70. 10.1016/j.ijrobp.2010.12.063
14.
BarbaroBVitaleRValentiniVIlluminatiSVecchioFMRizzoGet al. Diffusion-weighted magnetic resonance imaging in monitoring rectal cancer response to neoadjuvant chemoradiotherapy. Int J Radiat Oncol Biol Phys. (2012) 83:594–9. 10.1016/j.ijrobp.2011.07.017
15.
ElmiAHedgireSSCovarrubiasDAbtahiSMHahnPFHarisinghaniM. Apparent diffusion coefficient as a non-invasive predictor of treatment response and recurrence in locally advanced rectal cancer. Clin Radiol. (2013) 68:e524–31. 10.1016/j.crad.2013.05.094
16.
TateJGBamfordSJubbHCSondkaZBeareDMBindalNet al. COSMIC: the catalogue of somatic mutations in cancer. Nucleic Acids Res. (2019) 47:D941–7. 10.1093/nar/gky1015
17.
LievreABachetJBLe CorreDBoigeVLandiBEmileJFet al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. (2006) 66:3992–5. 10.1158/0008-5472.CAN-06-0191
18.
Luna-PerezPSeguraJAlvaradoILabastidaSSantiago-PayanHQuinteroA. Specific c-K-ras gene mutations as a tumor-response marker in locally advanced rectal cancer treated with preoperative chemoradiotherapy. Ann Surg Oncol. (2000) 7:727–31. 10.1007/s10434-000-0727-0
19.
CarpinettiPDonnardEBettoniFAsprinoPKoyamaFRozanskiAet al. The use of personalized biomarkers and liquid biopsies to monitor treatment response and disease recurrence in locally advanced rectal cancer after neoadjuvant chemoradiation. Oncotarget. (2015) 6:38360–71. 10.18632/oncotarget.5256
20.
GrimmingerPPDanenbergPDellasKArnoldDRodelCMachielsJPet al. Biomarkers for cetuximab-based neoadjuvant radiochemotherapy in locally advanced rectal cancer. Clin Cancer Res. (2011) 17:3469–77. 10.1158/1078-0432.CCR-10-2273
21.
Garcia-AguilarJChenZSmithDDLiWMadoffRDCataldoPet al. Identification of a biomarker profile associated with resistance to neoadjuvant chemoradiation therapy in rectal cancer. Ann Surg. (2011) 254:486–92. 10.1097/SLA.0b013e31822b8cfa
22.
SpitzFRGiaccoGGHessKLarryLRichTAJanjanNet al. p53 immunohistochemical staining predicts residual disease after chemoradiation in patients with high-risk rectal cancer. Clin Cancer Res. (1997) 3:1685–90.
23.
RebischungCGerardJPGayetJThomasGHamelinRLaurent-PuigP. Prognostic value of P53 mutations in rectal carcinoma. Int J Cancer. (2002) 100:131–5. 10.1002/ijc.10480
24.
ChenMBWuXYYuRLiCWangLQShenWet al. P53 status as a predictive biomarker for patients receiving neoadjuvant radiation-based treatment: a meta-analysis in rectal cancer. PLoS ONE. (2012) 7:e45388. 10.1371/journal.pone.0045388
25.
HuhJWLeeJHKimHR. Pretreatment expression of 13 molecular markers as a predictor of tumor responses after neoadjuvant chemoradiation in rectal cancer. Ann Surg. (2014) 259:508–15. 10.1097/SLA.0b013e31829b3916
26.
KudrimotiMLeeEYKangYAhmedMMohiuddinM. Genetic markers predictive of response to induction chemoradiotherapy for locally advanced rectal cancers. J Ky Med Assoc. (2007) 105:18–22.
27.
OsumiHShinozakiEYamaguchiKZembutsuH. Clinical utility of circulating tumor DNA for colorectal cancer. Cancer Sci. (2019) 110:1148–55. 10.1111/cas.13972
28.
MeddebRDacheZAAThezenasSOtandaultATanosRPastorBet al. Quantifying circulating cell-free DNA in humans. Sci Rep. (2019) 9:5220. 10.1038/s41598-019-41593-4
29.
DiehlFSchmidtKChotiMARomansKGoodmanSLiMet al. Circulating mutant DNA to assess tumor dynamics. Nat Med. (2008) 14:985–90. 10.1038/nm.1789
30.
OndrouskovaEHrstkaR. [Circulating tumor DNA in blood and its utilization as a potential biomarker for cancer]. Klin Onkol. (2015) 28(Suppl. 2):2s69–74. 10.14735/amko20152S69
31.
SefriouiDSarafan-VasseurNBeaussireLBarettiMGangloffABlanchardFet al. Clinical value of chip-based digital-PCR platform for the detection of circulating DNA in metastatic colorectal cancer. Dig Liver Dis. (2015) 47:884–90. 10.1016/j.dld.2015.05.023
32.
SpindlerKLPallisgaardNAndersenRFJakobsenA. Changes in mutational status during third-line treatment for metastatic colorectal cancer–results of consecutive measurement of cell free DNA, KRAS and BRAF in the plasma. Int J Cancer. (2014) 135:2215–22. 10.1002/ijc.28863
33.
TieJKindeIWangYWongHLRoebertJChristieMet al. Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer. Ann Oncol. (2015) 26:1715–22. 10.1093/annonc/mdv177
34.
KhierSLohanL. Kinetics of circulating cell-free DNA for biomedical applications: critical appraisal of the literature. Future Sci OA. (2018) 4:Fso295. 10.4155/fsoa-2017-0140
35.
MinarikMMinarikovaLHrabikovaMMinarikovaPHrabalPZavoralM. Application of cycling gradient capillary electrophoresis to detection of APC, K-ras, and DCC point mutations in patients with sporadic colorectal tumors. Electrophoresis. (2004) 25:1016–21. 10.1002/elps.200305770
36.
ProchazkovaKPavlikovaKMinarikMSumerauerDKodetRSedlacekZ. Somatic TP53 mutation mosaicism in a patient with Li-Fraumeni syndrome. Am J Med Genet A. (2009) 149a:206–11. 10.1002/ajmg.a.32574
37.
HinselwoodDCAbrahamsenTWEkstromPO. BRAF mutation detection and identification by cycling temperature capillary electrophoresis. Electrophoresis. (2005) 26:2553–61. 10.1002/elps.200410427
38.
FialaOPesekMFinekJBenesovaLBortlicekZMinarikM. Gene mutations in squamous cell NSCLC: insignificance of EGFR, KRAS and PIK3CA mutations in prediction of EGFR-TKI treatment efficacy. Anticancer Res. (2013) 33:1705–11. 10.1016/S0169-5002(13)70293-9
39.
LevyMBenesovaLLipskaLBelsanovaBMinarikovaPVeprekovaGet al. Utility of cell-free tumour DNA for post-surgical follow-up of colorectal cancer patients. Anticancer Res. (2012) 32:1621–6.
40.
DiehlFLiMHeYKinzlerKWVogelsteinBDressmanD. BEAMing: single-molecule PCR on microparticles in water-in-oil emulsions. Nat Methods. (2006) 3:551–9. 10.1038/nmeth898
41.
Team. RDC. A Language and Environment For Statistical Computing. Vienna: R Foundation for Statistical Computing (2008).
42.
ZittMMullerHMRochelMSchwendingerVGoebelGDevriesAet al. Circulating cell-free DNA in plasma of locally advanced rectal cancer patients undergoing preoperative chemoradiation: a potential diagnostic tool for therapy monitoring. Dis Markers. (2008) 25:159–65. 10.1155/2008/598071
43.
AgostiniMPucciarelliSEnzoMVDel BiancoPBriaravaMBedinCet al. Circulating cell-free DNA: a promising marker of pathologic tumor response in rectal cancer patients receiving preoperative chemoradiotherapy. Ann Surg Oncol. (2011) 18:2461–8. 10.1245/s10434-011-1638-y
44.
SunWLiGWanJZhuJShenWZhangZ. Circulating tumor cells: a promising marker of predicting tumor response in rectal cancer patients receiving neoadjuvant chemo-radiation therapy. Oncotarget. (2016) 7:69507–17. 10.18632/oncotarget.10875
45.
LiMXiaoWZhaoGQGuoZYangXLinSet al. Predictive value of circulating tumor DNA in locally advanced rectal cancer patients receiving neoadjuvant radiochemotherapy. J Clin Oncol. (2017) 35(Suppl. 15):e15125. 10.1200/JCO.2017.35.15_suppl.e15125
46.
YangLWangYShenLWanJDengWZhuJet al. Predicting treatment outcome of rectal cancer patients underwent neoadjuvant chemoradiotherapy by ctDNA: The potential use of ctDNA monitoring as organ-sparing approach. J Clin Oncol. (2018) 36(Suppl. 15):3608. 10.1200/JCO.2018.36.15_suppl.3608
47.
BenesovaLBelsanovaBSuchanekSKopeckovaMMinarikovaPLipskaLet al. Mutation-based detection and monitoring of cell-free tumor DNA in peripheral blood of cancer patients. Anal Biochem. (2013) 433:227–34. 10.1016/j.ab.2012.06.018
48.
TieJCohenJDWangYLiLChristieMSimonsKet al. Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer: a prospective biomarker study. Gut. (2018) 68:663–71. 10.1136/gutjnl-2017-315852
49.
HrebienSCitiVGarcia-MurillasICuttsRFenwickKKozarewaIet al. Early ctDNA dynamics as a surrogate for progression-free survival in advanced breast cancer in the BEECH trial. Ann Oncol. (2019) 30:945–52. 10.1093/annonc/mdz085
50.
OsumiHShinozakiEYamaguchiKZembutsuH. Early change in circulating tumor DNA as a potential predictor of response to chemotherapy in patients with metastatic colorectal cancer. Sci Rep. (2019) 9:17358. 10.1038/s41598-019-53711-3
51.
ReeceMSalujaHHollingtonPKarapetisCSVatandoustSYoungGPet al. The use of circulating tumor DNA to monitor and predict response to treatment in colorectal cancer. Front Genet. (2019) 10:1118. 10.3389/fgene.2019.01118
52.
KustanovichASchwartzRPeretzTGrinshpunA. Life and death of circulating cell-free DNA. Cancer Biol Ther. (2019) 20:1057–67. 10.1080/15384047.2019.1598759
53.
Vanpouille-BoxCAlardAAryankalayilMJSarfrazYDiamondJMSchneiderRJet al. DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity. Nat Commun. (2017) 8:15618. 10.1038/ncomms15618
54.
LyskjaerIKronborgCSRasmussenMHSorensenBSDemuthCRosenkildeMet al. Correlation between early dynamics in circulating tumour DNA and outcome from FOLFIRI treatment in metastatic colorectal cancer. Sci Rep. (2019) 9:11542. 10.1038/s41598-019-47708-1
55.
VymetalkovaVCervenaKBartuLVodickaP. Circulating cell-free DNA and colorectal cancer: a systematic review. Int J Mol Sci. (2018) 19:3356. 10.3390/ijms19113356
56.
RajaRKuzioraMBrohawnPZHiggsBWGuptaADennisPAet al. Early reduction in ctDNA predicts survival in patients with lung and bladder cancer treated with durvalumab. Clin Cancer Res. (2018) 24:6212–6222. 10.1158/1078-0432.CCR-18-0386
57.
HusainHMelnikovaVOKoscoKWoodwardBMoreSPingleSCet al. Monitoring daily dynamics of early tumor response to targeted therapy by detecting circulating tumor DNA in urine. Clin Cancer Res. (2017) 23:4716–4723. 10.1158/1078-0432.CCR-17-0454
58.
KhakooSCarterPDBrownGValeriNPicchiaSBaliMAet al. MRI tumor regression grade and circulating tumor DNA as complementary tools to assess response and guide therapy adaptation in rectal cancer. Clin Cancer Res. (2020) 26:183–92. 10.1158/1078-0432.CCR-19-1996
Summary
Keywords
rectal cancer, neoadjuvant chemoradiotherapy, circulating tumor ctDNA, prediction, prognosis, response, biomarker
Citation
Pazdirek F, Minarik M, Benesova L, Halkova T, Belsanova B, Macek M, Stepanek L and Hoch J (2020) Monitoring of Early Changes of Circulating Tumor DNA in the Plasma of Rectal Cancer Patients Receiving Neoadjuvant Concomitant Chemoradiotherapy: Evaluation for Prognosis and Prediction of Therapeutic Response. Front. Oncol. 10:1028. doi: 10.3389/fonc.2020.01028
Received
04 November 2019
Accepted
22 May 2020
Published
24 July 2020
Volume
10 - 2020
Edited by
Gloria Ravegnini, University of Bologna, Italy
Reviewed by
Chien-Feng Li, Chi Mei Medical Center, Taiwan; Olivier Feron, Université Catholique de Louvain, Belgium
Updates
Copyright
© 2020 Pazdirek, Minarik, Benesova, Halkova, Belsanova, Macek, Stepanek and Hoch.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Marek Minarik mminarik@elphogene.cz
This article was submitted to Pharmacology of Anti-Cancer Drugs, a section of the journal Frontiers in Oncology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.